Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

November 24, 2025

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

News Daily News

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

Yael L. Maxwell

March 10, 2025

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

News Daily News

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

January 16, 2024

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

News Daily News

New AHA/ACC Performance and Quality Metrics for Coronary Revascularization

Michael O'Riordan

July 28, 2023

More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA

News Daily News

More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA

Michael O'Riordan

July 18, 2023

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

News Daily News

Lipid Panels in Standard Precath Blood Draws? Researchers Say It’s Time

June 13, 2023

Swedish Study Adds to Evidence That Beta-blockers May Not Be Needed Long After MI

News Daily News

Swedish Study Adds to Evidence That Beta-blockers May Not Be Needed Long After MI

May 05, 2023

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

News Daily News

Physiologic Testing May ID Patients Who’ll Still Have Angina After PCI

Michael O'Riordan

March 31, 2023

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

News Daily News

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

August 19, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.